Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer

By afschroeder • August 22, 2025

Konecny GE, Davidson TM, Lebreton CL, Marsh LA, Chetram DK, Atkinson HJ, Larson MC, Oberg AL, Abdelaal N, Silverstein J, Jatoi A, Washburn A, Burton J, Dowdy S, Zhang L, Hallberg D, Velculescu VE, Slamon DJ, Wahner-Hendrickson AE. Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer. Int J Gynecol Cancer. 2025 Jul 28;35(10):102028. doi: 10.1016/j.ijgc.2025.102028. Epub ahead of print. PMID: 40839974.

Tags: CDK4/6 inhibitor, Cyclin-Dependent Kinases, Fellow, Hematology/Oncology, ovarian cancer, Palbociclib, Publications, targeted therapy

Related Posts

Dose-escalated stereotactic body radiotherapy re-irradiation in patients with recurrent head and neck cancer: a prospective phase 2 study using automated non-coplanar volumetric modulated arc therapy

Nikitas J, Ma TM, Cook K, Woods K, Kishan AU, Reddy VK, Hegde JV, John MS, Chai-Ho W, Wong D, Chu FI, Felix C, Tenn[...]

Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer

Sakowitz S, Tupper HI, Benjamin LN, Oh S, He T, Ronaghi R, Channick CL, Rosenberg BJ, Salehi-Rad R, Smith MI, Bando JM, Young TJ, Barjaktarvic[...]

Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical Therapy

Holzgreve A, Mona CE, Kimura K, Li X, Zhu Y, Tseng HR, Lee JK, Drakaki A, Garraway IP, Rettig MB, Calais J, Salavati A. Liquid[...]